ZFP36 Antibody

What is ZFP36 and why is it important in immunological research?

ZFP36 (also known as tristetraprolin or TTP) is an RNA-binding protein that plays a critical role in post-transcriptional regulation of gene expression, particularly in immune response. ZFP36 proteins are prominent inflammatory regulators linked to autoimmunity and cancer . They function by binding to AU-rich elements (AREs) in mRNA targets, typically leading to mRNA destabilization or translational repression. Recent research has revealed that ZFP36 is crucial in regulating T-cell activation, proliferation, and effector functions, making it an important target for immunological research .

How many ZFP36 paralogs exist and how can they be distinguished using antibodies?

There are three main paralogs in the ZFP36 family: ZFP36 (TTP), ZFP36L1 (BRF1), and ZFP36L2 (BRF2). These paralogs share significant sequence homology, particularly in their RNA-binding domains.

For antibody-based detection:

• Pan-ZFP36 antibodies, typically raised against conserved C-terminal peptides (such as APRRLPIFNRISVSE), can detect all three paralogs .

• Paralog-specific commercial antibodies can distinguish between individual family members .

• Western blot analysis may show multiple bands at ~40-50 kD for ZFP36, indicating several isoforms including hyperphosphorylated forms .

• ZFP36L1 shows a similar molecular weight to ZFP36, while ZFP36L2 is expected to run at ~62 kD .

What is the expression pattern of ZFP36 in T cells?

ZFP36 expression is dynamically regulated during T cell activation:

• Protein levels peak approximately 4 hours post-activation and gradually taper through 72 hours .

• ZFP36 can be re-induced by re-stimulation 3 days post-activation .

• Expression depends on both TCR stimulation (provided by anti-CD3) and co-stimulation (provided by co-cultured dendritic cells) .

• Similar patterns of transient ZFP36 induction occur in both CD4+ and CD8+ T cells .

• ZFP36 and ZFP36L1 are both induced by T-cell activation, while ZFP36L2 may not be detectable under standard activation conditions .

What types of samples can be analyzed using ZFP36 antibodies?

ZFP36 antibodies have been successfully used for analyzing:

• Primary mouse T cells (both CD4+ and CD8+)

• Bone marrow-derived dendritic cells

• Cell lines (e.g., 293 T-rex cells for overexpression studies)

• Tissues from animal models including wild-type and ZFP36 knockout mice

The antibodies work well for Western blot analysis, immunoprecipitation, and HITS-CLIP (High-throughput sequencing of RNA isolated by crosslinking immunoprecipitation) applications .

How can I generate and validate custom ZFP36 antisera for research use?

Generation process:

• Design a peptide targeting the conserved C-terminal region (such as APRRLPIFNRISVSE) that is present across ZFP36 family members .

• Commission antibody production in rabbits or other suitable host animals .

• Harvest antisera and purify using standard antibody purification techniques.

Validation steps:

• Confirm reactivity by ELISA against the immunizing peptide.

• Perform Western blotting with recombinant constructs of each paralog (ZFP36, ZFP36L1, ZFP36L2) to assess cross-reactivity and specificity .

• Compare signal between wild-type and ZFP36 knockout samples (expect ~50% reduction in signal if antibody detects multiple paralogs) .

• Validate functionality in immunoprecipitation experiments.

• Optimize antibody concentration for each application (Western blot, IP, CLIP).

What are the key considerations when using ZFP36 antibodies for HITS-CLIP experiments?

HITS-CLIP (UV-cross-linking and immunoprecipitation followed by high-throughput sequencing) is a powerful technique for identifying direct RNA targets of ZFP36:

Critical protocol considerations:

• Cross-linking optimization: Use UV irradiation to induce covalent bonds between ZFP36 and target RNAs, allowing stringent immunopurification .

• Antibody selection: Choose antibodies with high specificity and affinity for immunoprecipitation of ZFP36-RNA complexes.

• Controls: Include knockout/knockdown samples or IgG controls to identify non-specific binding.

• RNase titration: Carefully optimize RNase treatment to generate RNA footprints of appropriate size.

• Complex visualization: ZFP36-RNA complexes appear as a broad MW range with distinct biochemical properties including stability to heat, detergent, and high salt .

• Data analysis: Look for enrichment of AU-rich elements (AREs) in binding sites, particularly in 3'UTRs and coding sequences .

How can I differentiate between phosphorylated and non-phosphorylated forms of ZFP36 using antibodies?

Experimental approach:

• Western blot analysis: Multiple bands at ~40-50 kD typically indicate different phosphorylation states, with higher molecular weight bands representing hyperphosphorylated forms that predominate early after T cell activation .

• Phosphatase treatment: Treat samples with lambda phosphatase before Western blotting; a band shift to lower molecular weight confirms phosphorylation.

• Phospho-specific antibodies: Use commercial phospho-specific antibodies targeting known phosphorylation sites (e.g., MK2 phosphorylation sites).

• 2D gel electrophoresis: Separate proteins by both isoelectric point and molecular weight to resolve different phosphorylation states.

• Phos-tag gels: Use Phos-tag acrylamide gels which specifically retard the migration of phosphorylated proteins.

Data interpretation:

• Hyperphosphorylated forms typically indicate active regulation of ZFP36 activity .

• Phosphorylation status may differ between cell types and activation states, affecting ZFP36 function and target regulation .

How should I design experiments to study ZFP36 regulation of specific target mRNAs?

Comprehensive experimental approach:

• Target identification:

  • Perform HITS-CLIP to identify direct binding targets of ZFP36 .

  • Focus on transcripts with AU-rich elements in 3'UTRs or coding sequences .

• Validation of direct binding:

  • Create fluorescent reporters with intact 3'UTRs (WT-UTR) or variants with CLIP-defined ZFP36 binding sites deleted (Δ-UTR) .

  • Co-express reporters with ZFP36 in heterologous systems (e.g., 293 cells) .

• Functional assessment:

  • Compare mRNA abundance (by qRT-PCR) and protein levels (by Western blot) between WT and ZFP36 knockout T cells .

  • Perform ribosome profiling to assess both mRNA abundance and translation efficiency .

  • Analyze the kinetics of target expression following T cell activation .

• Correlation analysis:

  • Stratify targets based on ZFP36 binding magnitude to identify different regulatory patterns .

  • Examine differences between 3'UTR and CDS binding sites in terms of regulatory outcomes .

What controls should be included when using ZFP36 antibodies for Western blot analysis?

Essential controls:

• Genetic controls:

  • ZFP36 knockout samples (~50% reduction in pan-ZFP36 signal due to persistent expression of ZFP36L1) .

  • Samples with knockdown/knockout of specific paralogs to confirm antibody specificity.

• Expression controls:

  • Recombinant ZFP36, ZFP36L1, and ZFP36L2 protein standards to identify specific bands .

  • Time course of T cell activation to capture dynamic expression patterns .

• Technical controls:

  • Loading controls (e.g., β-actin, GAPDH) to normalize protein amounts.

  • Ladder/molecular weight markers to identify expected size ranges (ZFP36 ~36-50 kD, ZFP36L2 ~62 kD) .

  • Secondary antibody-only controls to identify non-specific binding.

• Validation approaches:

  • Compare results using multiple antibodies targeting different epitopes.

  • Include phosphatase-treated samples if studying phosphorylation states.

How can I address cross-reactivity issues when detecting ZFP36 family members?

Problem-solving strategies:

What are the key differences in using ZFP36 antibodies for immunoprecipitation versus Western blotting?

Application-specific considerations:

How should I interpret conflicting data from different ZFP36 antibodies?

When facing discrepancies between antibody results:

• Consider epitope location:

  • Antibodies targeting different regions may have different accessibility depending on protein conformation or binding partners.

  • Post-translational modifications may affect epitope recognition.

• Evaluate antibody specificity:

  • Compare results between wild-type and knockout samples .

  • Test against recombinant proteins of all three paralogs .

• Examine experimental conditions:

  • Different buffer conditions may affect antibody performance.

  • Cell/tissue type and activation state influence ZFP36 expression patterns .

• Cross-validate with orthogonal methods:

  • Combine protein detection with RNA analysis (qRT-PCR, RNA-seq).

  • Use tagged recombinant proteins in validation experiments.

• Consider inherent biological complexity:

  • ZFP36 exists in multiple isoforms with various phosphorylation states .

  • Expression patterns differ between cell types and activation stages .

How can ZFP36 antibodies be utilized to study the relationship between phosphorylation status and RNA-binding activity?

Experimental workflow:

• Differential extraction:

  • Isolate nuclear and cytoplasmic fractions to examine compartment-specific phosphorylation patterns.

  • Use phospho-specific antibodies to track ZFP36 modifications across cellular compartments.

• Phosphorylation-dependent binding analysis:

  • Perform sequential immunoprecipitation with phospho-specific and pan-ZFP36 antibodies.

  • Compare RNA targets bound to different phosphorylated forms using HITS-CLIP .

  • Examine binding kinetics throughout T cell activation timeline .

• Functional correlations:

  • Compare RNA stability and translation efficiency of targets bound by differently phosphorylated ZFP36.

  • Create phosphomimetic or phospho-dead ZFP36 mutants and analyze target regulation.

• Regulatory pathway integration:

  • Use inhibitors of kinases (e.g., MK2) known to phosphorylate ZFP36.

  • Correlate changes in phosphorylation status with RNA binding and target regulation.

What approaches can be used to study the interplay between ZFP36 and other RNA-binding proteins?

Multi-dimensional analysis strategies:

• Sequential CLIP:

  • Perform HITS-CLIP for ZFP36 followed by CLIP for other RBPs of interest .

  • Identify shared and distinct binding sites across targets.

• Co-immunoprecipitation studies:

  • Use ZFP36 antibodies to pull down protein complexes.

  • Analyze co-precipitated proteins by mass spectrometry or Western blotting.

  • Validate interactions through reciprocal co-IPs and proximity ligation assays.

• Competitive binding assays:

  • Design in vitro experiments with purified proteins and synthetic RNA containing binding sites.

  • Analyze how the presence of one RBP affects binding of others.

• Genetic interaction studies:

  • Create cell lines with ZFP36 knockout/knockdown combined with modulation of other RBPs.

  • Examine synergistic or antagonistic effects on shared target regulation.

• Structural biology approaches:

  • Use antibodies to purify ZFP36-containing complexes for structural studies.

  • Analyze how different RBPs may cooperate or compete at structural level.

How can ZFP36 antibodies be applied in single-cell analysis techniques?

Innovative methodological approaches:

• Single-cell Western blotting:

  • Optimize ZFP36 antibody protocols for microfluidic or capillary-based single-cell Western platforms.

  • Compare ZFP36 expression levels across individual cells within heterogeneous populations.

• Mass cytometry (CyTOF):

  • Conjugate ZFP36 antibodies with metal isotopes for high-dimensional analysis.

  • Simultaneously examine ZFP36 expression alongside cell surface markers and intracellular signaling molecules.

• Imaging mass cytometry:

  • Apply metal-labeled ZFP36 antibodies to tissue sections.

  • Create high-resolution spatial maps of ZFP36 expression in tissue microenvironments.

• Spatial transcriptomics integration:

  • Combine ZFP36 protein detection with in situ RNA analysis.

  • Correlate ZFP36 localization with target mRNA distribution at single-cell resolution.

What considerations are important when designing experiments to target ZFP36 for therapeutic applications?

Translational research framework:

• Inhibition strategies assessment:

  • Use antibodies to evaluate the efficacy of small molecule inhibitors in modulating ZFP36 activity .

  • Monitor changes in phosphorylation status and target binding upon inhibitor treatment.

• Context-dependent functions:

  • Compare ZFP36 activity across different immune cell types using cell-type specific antibody-based assays.

  • Assess how inhibition affects diverse immunological contexts (viral infection, cancer, autoimmunity) .

• Target specificity validation:

  • Develop assays to ensure therapeutic approaches specifically target ZFP36 without affecting paralogs.

  • Use paralog-specific antibodies to monitor off-target effects .

• Efficacy monitoring:

  • Create antibody-based assays to track ZFP36 activity in ex vivo samples during therapeutic trials.

  • Correlate changes in ZFP36 function with clinical outcomes.

• Safety assessment:

  • Monitor the balance between enhanced immunity and potential inflammatory/autoimmune effects .

  • Track ZFP36 target regulation in multiple tissues to predict off-target toxicities.